Impact of A Nutritional Supplements' Combination (FERTILIS) on Male Infertility

Infertility, Male Clinical Trial

— FERTILIS  

Official title:

Impact of A Nutritional Supplements' Combination (FERTILIS) On Male Infertility: A Monocentric Double Blind Randomized Placebo Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04193358
• Other study ID #: FERTILIS-349
• Status: Recruiting
• Phase: N/A
• Start date: February 17, 2020
• Est. completion date: December 30, 2022

Study information

• Verified date: March 2021
• Source: Les Laboratoires des Médicaments Stériles
• Contact: Amina Radoui, MSc
• Phone: 0021698709295
• Email: a.radoui[@]medis.com.tn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Infertility is a major health problem affecting up to 15% of couples of reproductive age globally. For several years, it was assumed that most reproductive problems could be attributed to the female partner, but research in recent years has demonstrated that males were solely responsible for 20-30% of infertility cases and contributed to 50% of infertility cases overall. The term ''male infertility'' does not constitute a defined clinical syndrome, but rather a collection of different conditions exhibiting a variety of etiologies.

It is far increasingly known that reactive oxygen species (ROS) are of significant pathophysiological importance in the etiology of male infertility. ROS are highly reactive oxidizing agents belonging to the class of free radicals containing one or more unpaired electrons, which are continuously being generated through metabolic and pathophysiologic processes. It has been suggested that oxidants interfere with normal sperm function via membrane lipid peroxidation and fragmentation of nucleic acids, which result in sperm dysfunction. Due to the sperm cell membrane abundance of polyunsaturated fatty acids (PUFAs) and the capacity of sperm to generate ROS, human spermatozoa are highly susceptible to oxidative stress.

Since growing evidence indicates that oxidative stress can be a primary cause of male infertility, non-enzymatic antioxidants play a significant protective role against oxidative damages and lipid peroxidation. In addition, micronutrients and antioxidants are often used with good results in men with idiopathic infertility.

Keeping in view the main protection provided by seminal plasma antioxidants against oxidative damages, a previous study showed that the dietary management with an eight nutritional supplements' combination, similar to this study's product and containing antioxidants, achieved a significant improvement in sperm quality up to a completely normal semen analysis. Also, another study confirmed the hypothesis that the combination of individual nutritional supplements as described in literature showed significantly better results than the sum of the effects of single administration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 30, 2022
• Est. primary completion date: December 30, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Male = 20 years of age

• Attending the Department of Obstetrics and Gynecology of Farhat Hached University Hospital, Sousse, Tunisia, for consultation or semen analysis as part of infertility investigations

• Diagnosis of oligozoospermia (WHO 2010 definition)

• Diagnosis of Asthenozoospermia (WHO 2010 definition)

• Diagnosis of teratozoospermia1 (WHO 2010 definition)

• Diagnosis of idiopathic infertility

• Couple is candidate for Intrauterine Insemination (IUI), In Vitro Fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI).

Exclusion Criteria:

• Inclusion visit (prior to treatment initiation): Patients will be selected during this initial visit if they meet all inclusion and none of the exclusion criteria.

• Randomization visit: around 1-week post inclusion visit: Patients will be given either of study interventions.

• Follow up visit 1-month post treatment initiation: Patients will be given study interventions' refill for 1 month.

• Follow up visit 2-months post treatment initiation: Patients will be given study interventions' refill for another month.

• Follow up visit 3-months post treatment initiation: Patients will undergo laboratory assessment.

• Follow up visits every 3-months post Visit: Patients' female partner will undergo laboratory and clinical assessment.

• End of trial (CLOSING) visit 24-months post treatment initiation: Patients' female partner will undergo laboratory and clinical assessment.

Related Conditions & MeSH terms

• Infertility
• Infertility, Male
• Subfertility, Male

Intervention

Dietary Supplement:
• FERTILIS HOMME®
L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg

Other:
• PLACEBO
Sugar pills

Locations

Country	Name	City	State
Tunisia	Farhat Hached Hospital	Sousse

Sponsors (1)

Lead Sponsor	Collaborator
Les Laboratoires des Médicaments Stériles

Country where clinical trial is conducted

Tunisia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sperm DNA fragmentation Index (DFI)	To evaluate the effect of a nutritional supplement's combination of 8 active compounds (L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg; FERTILIS HOMME®, Les Laboratoires MédiS, Tunisia), on sperm DNA fragmentation index (DFI).	3 months
Secondary	Sperm quantity	Ejaculatory volume (ml) and sperm cell density (mill/ml	3 months
Secondary	Sperm quality	Sperm morphology and sperm total motility/progressive motility	Up to 3 months
Secondary	Occurrence of spontaneous pregnancy		Through study completion, an average of 2 years
Secondary	Occurrence of pregnancy consecutive to Assisted Reproductive Technology (ART)		Through study completion, an average of 2 years
Secondary	Fertilization rate during in vitro fertilization (IVF)		Up to 3 months
Secondary	Embryo cleavage rate and embryo quality during intracytoplasmic sperm injection (ICSI)		Up to 3 months
Secondary	Achievement of clinical pregnancy		Through study completion, an average of 2 years
Secondary	Achievement of live birth		Through study completion, an average of 2 years
Secondary	Number of Adverse Events	To assess the safety of the study product	Through study completion, an average of 2 years